Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome
10.3760/cma.j.issn.0253-3758.2009.10.010
- VernacularTitle:早期阿托伐他汀联合普罗布考治疗对急性冠状动脉综合征患者血管内皮功能的影响
- Author:
Xiao-Yan ZHENG
1
;
Ling LIU
;
Shui-Ping ZHAO
Author Information
1. 中南大学湘雅二医院
- Keywords:
Coronary disease;
Endothelium;
vascular;
Antilipemic;
agents
- From:
Chinese Journal of Cardiology
2009;37(10):900-903
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To evaluate the effects of combined atorvastatin and probucol use on endothelial function in patients with acute coronary syndrome (ACS). Methods Thirty patients with ACS were randomized to receive atorvastatin (20 mg/d) and probucol (500 mg/d, combination group, n = 15) or atorvastatin (20 mg/d) alone (atorvastatin group) within 24 h after admission for 4 weeks. Endothelium-dependent flow-mediated dilatation (FMD) and endothelium-independent sublingual nitroglycerin-mediated dilatation (NMD) as well as the levels of lipids and C-reactive protein were assessed at baseline, 1 week and 4 weeks after therapy. Results Compared to baseline, the levels of total cholesterol, LDL-C and C-reactive protein were significantly reduced after 1 week and 4 weeks in both groups, FMD equally increased after 1 week in both groups (atorvastatin group: 3.75%±0.78% vs. 1.09%±0.44%, combination group: 3.67%±0.36% vs. 1.24%±0.37%, P<0.01). Post4 weeks therapy, FMD increase was significantly higher in combination group (3.67%±0.36% at 1 week vs. 6.85%±0.64% at 4 weeks, P <0.01) than that in atorvastatin group (3.75%±0.78% vs. 3.80%±0.31%, P=0.954). NMD also equally and increased over 4 weeks in two groups (P<0.01 vs. baseline). There was no correlation between the change in FMD/NMD and the changes in lipids or C-reactive protein levels. Conclusions The combined atorvastatin and probucol therapy early after ACS is superior to atorvastatin alone on improving endothelial function.
